UCP1 and Hepatic steatosis: Our findings are consistent with those of previous studies reporting favorable metabolic phenotypes induced by empagliflozin in obese mice fed a high-fat diet, in which an increase in energy expenditure, elevated expression of UCP1 in WAT, attenuation of inflammation, and alleviation of hepatic steatosis were observed (Xu et al., 2017, 2019).